卡瑞利珠单抗联合mFOLFOX6方案治疗晚期结直肠癌的效果及对免疫相关指标的影响

Effect of Camrelizumab Combined with mFOLFOX6 Regimen in the Treatment of Advanced Colorectal Cancer and Its Influence on Immune Related Indicators

目的:分析晚期结直肠癌患者接受卡瑞利珠单抗联合mFOLFOX6方案治疗效果及对免疫相关指标的影响。方法:将赣州市肿瘤医院2020年3月-2022年3月收治的50例晚期直肠癌患者用随机数字表法分为对照组(n=25,给mFOLFOX6方案治疗)、分析组(n=25,给予mFOLFOX6方案联合卡瑞利珠单抗治疗),比较两组总有效率、免疫相关指标[辅助型T细胞1(Th1)、辅助型T细胞2(Th2)]、血清肿瘤标记物[糖类抗原19-9(CA19-9)、糖类抗原242(CA242)、癌胚抗原(CEA)]水平及不良反应。结果:分析组疾病控制率(84.00%)高于对照组(52.00%),差异有统计学意义(P<0.05);分析组治疗后3 d Th1、Th1/Th2均低于对照组,Th2高于对照组,差异均有统计学意义(P<0.05);分析组治疗后3 d的CA19-9、CEA、CA242水平均低于对照组(P<0.05);治疗期间分析组手足皮肤反应、周围神经炎腹泻、肝功能异常、腹泻的发生率与对照组比较差异均无统计学意义(P>0.05)。结论:较单纯mFOLFOX6方案,联合卡瑞利珠单抗治疗晚期结直肠癌能有效提高疾病控制率,减轻免疫抑制,降低肿瘤标记物水平,安全可靠,值得推广应用。

Objective:To analyze the therapeutic effect of Camrelizumab combined with mFOLFOX6 regimen and the influence of immune related indicators in patients with advanced colorectal cancer.Method:A total of 50 patients with advanced colorectal cancer admitted to Ganzhou Cancer Hospital from March 2020 to March 2022 were randomly divided into the control group(n=25,treated with mFOLFOX6 regimen)and the analysis group(n=25,treated with mFOLFOX6 regimen combined with Camrelizumab),the total effective rate,immune related indicators(Th1,Th2),serum tumor markers(CA19-9,CA242,CEA)and adverse reactions of the two groups were compared.Result:The disease control rate in the analysis group(84.00%)was higher than that in the control group(52.00%)(P<0.05).Three days after treatment,Th1 and Th1/Th2 in the analysis group were lower than those in the control group,and Th2 was higher than that in the control group(P<0.05).Three days after treatment.the levels of CA19-9,CEA and CA242 in the analysis group after treatment were lower than those in the control group(P<0.05).There were no significant differences between the analysis group and the control group in the incidence of hand and foot skin reaction,peripheral neuritis and diarrhea,abnormal liver function and diarrhea during treatment(P>0.05).Conclusion:Compared with the mFOLFOX6 regimen alone,the combination of Camrelizumab in the treatment of advanced colorectal cancer can effectively improve the disease control rate,reduce immunosuppression,and reduce the level of tumor markers.It is safe and reliable,and is worth popularizing.